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ABSTRACT 
BACKGROUND: Tuberculosis is a common health problem in the world.  Sudan is among the 
countries with the highest prevalence for tuberculosis andHBV, HCV infections. 
Co infection with viral hepatitis (HBV, HCV) among tuberculosis patients increases the risk of 
hepatotoxicity occurring during tuberculosis treatment, so itis important to know the sero-
prevalence of hepatitis B and Cviruses among tuberculosis patients. 
OBJECTIVES: To investigate seroprevalence of HBV and HCV among adult tuberculosis patients in 
tuberculosis center at Tropical Diseases Teaching Hospital (TDH).  
METHODOLOGY: This is a prospective cross sectional study, conducted in the period from 
December 2010 to October 2011 in tuberculosis center in TDH- Sudan. 200 adult tuberculosis 
patients (age 19years and above) were enrolled in this study, data were collected by using 
questionnaire. All patients' blood samples were tested for HBsAg and hepatitis C virus antibodies. 
Results were analyzed by using SPSS16 (Statistical package for social science16) 
RESULTS: A total number of 200 confirmed tuberculosis patients were studied. 127 patients 
(63.5%) were males. The seroprevalence of HBV and HCV in this study were9.5% and 3.5% 
respectively.Two patients (1%) were infected with both infections. The HBV vaccination among 
the study group was 6%. 
CONCLUSION: The HBV andHCV infectionsare common among tuberculosis patients with 
seroprevalence of 9.5%and 3.5% for HBV and HCV respectively. Our study also showed that there 
are multiple risk factors for contracting HBV and HCV infections in our patients, so screening for 
these virusesshould be included in the national TB control program. 
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uberculosis is one of the most 
important health problems in the world 
caused by mycobacterium tuberculosis 
complex1.Two billion of people are affected 
worldwide2, its global incidence is 
219/100.000 and its death rate is 25/100.0003.
Sudan is among the highest prevalence 
countries for TB in the East Mediterranean 
region and shouldering 11-15% of the TB 
burden in this region3. The estimated 
prevalence of the diseasein Sudan is209 cases 
per 100.000 populations  and the majority of 
patientsare in their productive ages. 
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The overall estimated death rate related to 
TBin Sudan is 24 per 100.000 populations3.
There are 345 TB centers in Sudan3, 74
percent of them in Khartoum state4 all are 
well equipped with aids for diagnosis and 
treatment3.
TB producesits lethal affect through the 
disease itself or by hepatotoxicity occurring 
during treatment. 
There are several factors that increase this 
hepatotoxicity of anti-tuberculosis therapy 
one of them is viral hepatitis namely HBV 
and HCV.  
HBV affect more than two billion people 
worldwide and 350 million people are chronic 
carrier5. Sudan is among countries with high 
endemicity of more than 8%5 and the 
seroprevalence of HBV is 5.1 and 5.6% 
among blood donors in northern and central 
Sudan respectively6. The HCV worldwide 
affects 170 million7and the seroprevalence in 
T
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Sudan equals 2.2 % - 4.8 %5 with 
predominance of genotype48.
The presence of concomitant infection of 
tuberculosis and viral hepatitis namely HBV 
and HCV during treatment of tuberculosis 
increases the risk of hepatotoxicity as many 
studies reveal9 and even may lead to death. 
This reflects the importance of screening of 
HBV and HCV among tuberculosis patients10 
to decrease death and comorbidities among 
tuberculosis patients.  
Methodology: 
This is a prospective cross sectional hospital-
based study. The study populations were 200 
confirmed TB patients and were on 
antituberculous treatment and managed in TB 
center during the period 2010-2011, atTDH in 
the capital Khartoum. TB center iswell 
equipped with aids for diagnosis and 
treatment supervised by Sudan National TB 
programand is run by trained medical 
personnel who verify the documentation and 
transfer of patient data from the hospital 
medical records into an electronic software 
system.   
TDH is a referral Ministry of Health hospital, 
Sudan. This hospital was founded in 1974 for 
research, service, and training on tropical and 
infectious diseases, mainly visceral 
leishmaniasis, malaria, TB and 
schistosomiasis.  
The demographic and clinical data 
werecollected via questionnaires adopted for 
the study.Blood samples drawn under aseptic 
conditions from patients diagnosed with 
tuberculosis were tested for HBsAg, and HCV 
antibodies. SD BIOLINE HBsAg test, which 
is an in-vitro immunochromatographic, one 
step assay designed for qualitative 
determination of HBsAg in human serum or 
plasma was used for detection of HBV. This 
test has relativesensitivity of 100 percent, and 
relative specificity of 100 percent. On the 
other hand,   the   SDBIOLINE  HCV    test,  
Table1: Demographic features of 200 pulmonary TB study population 
 Frequency Percent Valid percent 
Sex 
Male 127 63.5 63.5 
Female 73 36.5 36.5 
Age <40years 140 70 70 ≥40years 60 30 30 
Marital status Single 84 58 58 
Married 116 42 42 
Residence Urban 29 14.5 14.5 Rural 171 85.5 85.5 
Occupation 
Employed 115 57.5 57.5 
Unemployed 85 42.5 42.5 
Education Educated 135 67.5 67.5 
Illiterate 65 32.5 32.5 
which is an  immune chromatographic  test  
for  qualitative  detection of antibodies  
specific  to HCV, in human serum plasma  or  
whole blood was used for detection of HCV. 
It has sensitivity of 100 percent and 
specificity of 99.4 percent. All tests were 
done in a well-equipped laboratory by well 
expertise personnel in TDH. Computer 
assisted analysis, using statistical program for 
social sciences (SPSS) version 16, was 
employed. 
The study was approved by the Research and 
Ethics Committee of tropical Diseases 
Hospital, Sudan. Written consent was taken 
from selected subjects prior to questionnaire 
filling and blood sampling. Patient’s 
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confidentiality, privacy and dignity were 
guaranteed; also the information obtained 
remained strictly protected. This was 
achieved through the safe keeping of the 
completed forms and the entry of 
personaldata on computer only as a code and 
sending blood samples to the laboratory as 
codes numbers. 
Results: 
The demographic features of 200 pulmonary 
TB study patients were illustrated in Table 1. 
140 (70%) patients were found in the age 
group less than 40years and 127 (63.5%) 
patients were males, 171(85.5%) patients 
were from rural areas. 116 (58%) 
patientsweremarried, 65(32.5%) patients were 
illiterate. Only 24 (12%) patients have 
governmental jobs. 
History of blood transfusion, jaundice, 
vaccination against HBV was found in 
19(9.5%) , 49 (24.5%) and 12(6%) of patient 
srespectively.
Table 2: Risk factors for HBV and HCV infection in all patients with TB 
 
Frequency Percent Valid percent 
Blood transfusion Yes 19 9.5 9.5 
No 181 90.5 90.5 
Jaundice Yes 49 24.5 24.5 
No 151 75.5 75.5 
HBV vaccination Yes 12 6 6 
No 188 94 94 
I.V drug abuse Yes 0 0.00 0.00 
No 200 100 100 
Table3: Demographic features and risk factors ofpatients with HBV positive screen  
 Frequency Percent Valid percent 
Sex 
Male 16 84.2 84.2 
Female 3 15.8 15.8 
Age 
<40years 12 63.2 63.2 
≥40years 7 36.8 36.8 
Marital status 
Single 10 52.3 52.3 
Married 9 47.7 47.7 
Residence 
Urban 12 63.2 63.2 
Rural 7 36.8 36.8 
Occupation 
Employed 12 63.2 63.2 
Unemployed 7 36.8 36.8 
Education 
Educated 12 63.2 63.2 
Illiterate 7 36.8 36.8 
Blood transfusion 
Yes 0 0.00 0.00 
No 19 100 100 
Jaundice 
Yes 3 15.8 15.8 
No 16 84.2 84.2 
HBV vaccination 
Yes 0 0.00 0.00 
No 19 100 100 
I.V drug abuse 
Yes 0 0.00 0.00 
No 19 100 100 
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On the other hand none of them gave history 
of intravenous drug abuseTable2. 
The seroprevalence of  HBV in the study was 
9.5% (19 patients), 16(84.2%) of them were 
males and15(78.9%) were in the age group 
less than 40 years. All patients with positive 
screening test were not vaccinated against 
HBV (Table 3). 
Table 4 shows demographic features and risk 
factors of patients with HCV positive 
screen.Two patients (1%) were infected with 
both infections. The HBV vaccination among 
the study group was (6%). 
Discussion:  
The present study represents- to the best of 
our knowledge-the first studyin Sudan about 
the seroprevalence of hepatitis B and C virus 
among TB patients. Our study is the first to 
indicate that infection with HBV and HCV is 
a significant problem among patients with 
tuberculosis in Sudan. Although it is a 
common problem in Sudan, hepatitis B and C 
viruses screen was not done as routine as HIV 
test among patients with TB, this may be due 
to limited resources. 
Co infection with hepatitis B or C Viruses 
among tuberculosis patients potentiate the risk 
of antituberculous therapy induced 
hepatotoxicity11,so we should exercise caution 
and carefully monitor our patients for drugs 
associated hepatotoxicity. 
In this study the seroprevalence of hepatitis B 
virus was 9.5% and it was higher than the 
seroprevalence among general population and 
 
Table4: Demographic features and risk factors of patients withHCV positive screen. 
 
Frequency Percent Valid percent 
Sex Male 6 85.7 85.7 Female 1 14.3 14.3 
Age <40years 4 57.1 57.1 ≥40years 3 42.9 42.9 
Marital status Single 3 42.9 42.9 Married 4 57.1 57.1 
Residence Urban 2 28.6 28.6 Rural 5 71.4 71.4 
Occupation Employed 6 85.7 85.7 Unemployed 1 14.3 14.3 
Education Educated 3 42.9 42.9 Illiterate 4 57.1 57.1 
Blood transfusion Yes 1 14.3 14.3 No 6 85.7 85.7 
Jaundice Yes 0 0.00 0.00 No 7 100 100 
I.V drug abuse Yes 0 0.00 0.00 No 7 100 100 
blood donors in Sudan (6.8%)5
(5.6%)6respectively and lower than 
seroprevalence of  HBV in Brazil which 
showed seroprevalence of 14.6% among 
patients with tuberculosis12.This may be due 
to thehigh prevalence (14%) of  HBV in that 
country13.Also the seroprevalence of HBV in 
our study is lower than in India which showed 
seroprevalence of HBV among pulmonary 
tuberculosis patients of 15%14despite the 
relatively low seroprevalence of HBV in that 
country(4%)15.
The majority (78.9%) of our patients who 
were positive forHBV wasyoung (< 40 years). 
The seroprevalence of HBV was 
staticthereafter indicating that being young-< 
40years-is possibly a risk factor for 
contracting HBV infection which is 
compatible with the literature.Going with 
reports, 12(57.8%) patients positiveforHBV 
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in this study were from rural areas with low 
socioeconomic status. 
Similar to a previous study in Eastern Sudan6,
the majority (84.2%) of our HBV positive 
patients were males, accusinggender as a risk 
factor for HBV infection. 
Our study also showed none of HBV positive 
patients have history of blood transfusion and 
this may reflect the effectiveness of 
themeasures taken byour blood banks and 
thisis consistent with a study done in Sudan in 
general population which showed no 
association with blood transfusion and HBV 
infection5.
The majority (84.2%) of our HBV positive 
patients have no history of jaundice, and this 
reflect the fact that the disease commonly 
occurs in subclinical asymptomatic pattern as 
mentioned in literature. 
Vaccination rate against HBV was very low 
(6%)among the population studied and none 
of HBV positive patients was vaccinated.This 
highlights the need forintensifying 
thevaccination program in our community. 
In this study the seroprevalence of  HCV  
among tuberculosis patients was 3.5%and this  
was higher than that  among  general 
population in Gezira area (2.2%)(8) and lower 
than that among tuberculosis patients (19.4%) 
reported inhigh epidemic  country in which it 
was attributed to high risk factors such as 
intravenous drug abuse16.
Our results showed there are four patients 
(52.1%) among HCV positive patients in age 
group less than 40years, and one patient 
(14.3%) in age group 40-60years and two 
patients (28.6%) in age group more than 
60years, and this differ from the literature 
which showed that the infection was common 
in age from40-49years.Our figures are small 
so it is difficult to draw conclusions. Further 
studies may be needed in the future to 
determine the others risk factors among our 
patients such as intravenous drug abuse. 
Our results showed that six (85.7%) patients 
with HCV were males and this is consistent 
with literature16.History of jaundice among 
HCV positive patientswas lacking, and this is 
consistent with reports from elsewhere. This 
highlights the importance of screening for 
HCV and doing liver function test among 
patients with high risk for infection such as 
TB patients so as to discover the occult 
infection early.Before drawing conclusions 
we have to admit that the numbers in this 
study were very small, so larger studies are 
highly recommended to support or disprove 
our results. 
Conclusion: 
The present study showed that hepatitis B and 
Cviruses’ infection is common among 
tuberculosis patients.Infection with HBV or 
HCV may occur without any history of 
jaundice. Male gender, age less than 40years 
and low socioeconomic status are main risk 
factors for HBV and HCV infection which are 
shared with TB. No role for blood transfusion 
in transmission of HBV or HCV infection in 
this study. 
There is low coverage of HBV Vaccination 
among the study group. Our study also 
showed that are multiple risk factors for 
contracting TB and (HBV, HCV) infections, 
so screening for these virusesshould be 
included in the national TB control 
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